Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017 (2017), Article ID 1506824, 5 pages
https://doi.org/10.1155/2017/1506824
Research Article

Dynamics of Neutrophils-to-Lymphocyte Ratio Predict Outcomes of PD-1/PD-L1 Blockade

1Drug Development Unit, Sarah Cannon Research Institute, London, UK
2University Hospital of Basel, Basel, Switzerland
3The University College London Cancer Institute, London, UK
4Department of Medical Oncology, University of Ioannina, Ioannina, Greece

Correspondence should be addressed to Michele Moschetta

Received 20 August 2017; Accepted 5 November 2017; Published 28 November 2017

Academic Editor: Ilaria G. Zizzari

Copyright © 2017 Michele Moschetta et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Goodman, S. P. Patel, and R. Kurzrock, “PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas,” Nature Reviews Clinical Oncology, 2016. View at Publisher · View at Google Scholar
  2. J. Hamanishi, M. Mandai, N. Matsumura, K. Abiko, T. Baba, and I. Konishi, “PD-1/PD-L1 blockade in cancer treatment: perspectives and issues,” International Journal of Clinical Oncology, vol. 21, no. 3, pp. 462–473, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. D. M. Pardoll, “The blockade of immune checkpoints in cancer immunotherapy,” Nature Reviews Cancer, vol. 12, no. 4, pp. 252–264, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. V. A. Boussiotis, “Molecular and biochemical aspects of the PD-1 checkpoint pathway,” The New England Journal of Medicine, vol. 375, no. 18, pp. 1767–1778, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. S. L. Topalian, J. M. Taube, R. A. Anders, and D. M. Pardoll, “Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy,” Nature Reviews Cancer, vol. 16, no. 5, pp. 275–287, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Galon, A. Costes, F. Sanchez-Cabo et al., “Type, density, and location of immune cells within human colorectal tumors predict clinical outcome,” Science, vol. 313, no. 5795, pp. 1960–1964, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. R. B. Holmgaard, D. Zamarin, A. Lesokhin, T. Merghoub, and J. D. Wolchok, “Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors,” EBioMedicine, vol. 6, pp. 50–58, 2016. View at Publisher · View at Google Scholar
  8. W. Joost Lesterhuis, A. Bosco, M. J. Millward, M. Small, A. K. Nowak, and R. A. Lake, “Dynamic versus static biomarkers in cancer immune checkpoint blockade: Unravelling complexity,” Nature Reviews Drug Discovery, vol. 16, no. 4, pp. 264–272, 2017. View at Publisher · View at Google Scholar · View at Scopus
  9. D. J. Pinato, C. Stavraka, M. J. Flynn et al., “An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials,” PLoS ONE, vol. 9, article e83279, no. 1, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. H.-T. Arkenau, J. Barriuso, D. Olmos et al., “Prospective validation of a prognostic score to improve patient selection for oncology phase I trials,” Journal of Clinical Oncology, vol. 27, no. 16, pp. 2692–2696, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Grigg and N. A. Rizvi, “PD-L1 biomarker testing for non-small cell lung cancer: Truth or fiction?” Journal for ImmunoTherapy of Cancer, vol. 4, no. 1, article 48, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. I. Garrido-Laguna, F. Janku, C. Vaklavas et al., “Validation of the Royal Marsden Hospital prognostic score in patients treated in the phase i clinical trials program at the MD Anderson Cancer Center,” Cancer, vol. 118, no. 5, pp. 1422–1428, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Kawaguchi, M. Takada, A. Kubo et al., “Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: A comprehensive analysis of 26,957 patients with NSCLC,” Journal of Thoracic Oncology, vol. 5, no. 5, pp. 620–630, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. J. A. Kuzman, D. D. Stenehjem, J. Merriman et al., “Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma,” BMC Urology, vol. 17, article 1, no. 1, 2017. View at Publisher · View at Google Scholar · View at Scopus
  15. S. J. Bagley, S. Kothari, C. Aggarwal et al., “Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer,” Lung Cancer, vol. 106, pp. 1–7, 2017. View at Publisher · View at Google Scholar · View at Scopus
  16. W. Chua, K. A. Charles, V. E. Baracos, and S. J. Clarke, “Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer,” British Journal of Cancer, vol. 104, no. 8, pp. 1288–1295, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Zhang, Y. Zong, M. Liu, Y. Tai, Y. Cao, and C. Hu, “Prediction outcome in breast cancer patients using test parameters from complete blood count,” Molecular and Clinical Oncology, vol. 4, no. 6, pp. 918–924, 2016. View at Google Scholar
  18. L. Käsmann, L. Bolm, S. E. Schild, S. Janssen, and D. Rades, “Neutrophil-to-Lymphocyte Ratio Predicts Outcome in Limited Disease Small-cell Lung Cancer,” Lung, vol. 195, no. 2, pp. 217–224, 2017. View at Publisher · View at Google Scholar · View at Scopus
  19. S. L. Highfill, Y. Cui, A. J. Giles et al., “Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy,” Science Translational Medicine, vol. 6, article 237ra67, no. 237, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. O. Draghiciu, J. Lubbers, H. W. Nijman, and T. Daemen, “Myeloid derived suppressor cells—an overview of combat strategies to increase immunotherapy efficacy,” OncoImmunology, vol. 4, no. 1, Article ID 954829, 11 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus